Benitec Biopharma (BNTC) Current Assets (2019 - 2025)

Benitec Biopharma has reported Current Assets for 7 years, with the latest figure at $189.6 million in Q4 2025.

• Quarterly Current Assets rose 140.87% year-over-year to $189.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $189.6 million (up 140.87% YoY) and the FY2025 annual result came in at $98.5 million, up 90.65% from the prior year.
• Current Assets advanced to $189.6 million in Q4 2025 per BNTC's latest filing, from $95.1 million in the prior quarter.
• Over five years, Current Assets peaked at $189.6 million in Q4 2025 and troughed at $3.7 million in Q2 2023.
• A 5-year average of $43.1 million and a median of $18.8 million in 2021 frame the typical range for Current Assets.
• The sharpest annual moves came in 2022 and 2024: Current Assets plunged 76.61% in 2022, then surged 1285.73% in 2024.
• Over 5 years, Current Assets stood at $12.7 million in 2021, then slipped by 13.39% to $11.0 million in 2022, then jumped by 89.49% to $20.8 million in 2023, then soared by 278.5% to $78.7 million in 2024, then jumped by 140.87% to $189.6 million in 2025.
• According to Business Quant data, Current Assets over the past three periods registered $189.6 million, $95.1 million, and $98.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.